Evidence of covalent interaction of fumaric acid esters with sulfhydryl groups in peptides
- 21 September 2005
- journal article
- research article
- Published by Wiley in Journal of Mass Spectrometry
- Vol. 40 (10), 1309-1318
- https://doi.org/10.1002/jms.910
Abstract
Fumaric acid esters, namely dimethylfumarate, have been used for the treatment of psoriasis for many years. Still, their mode of action is not fully clear. Because addition of nucleophiles to the double bonds of fumarates can occur (Michael analogous addition), a study of the interaction of fumarates with cysteine and cysteine‐containing peptides possessing nucleophilic sulfhydryl group was carried out. Experiments were performed in aqueous medium at pH 7.4 and at 37 °C to simulate physiological conditions. It was proven by mass spectrometric measurements using an ion‐trap and time‐of‐flight instrument that a covalent bond can form between fumarates and the sulfhydryl group of cysteine or cysteinyl residues in peptides. Structures of the interaction products were elucidated by multistage mass spectrometry applying collision‐induced dissociation. Higher reactivity of dimethylfumarate in comparison to monomethylfumarate and fumaric acid was observed. Copyright © 2005 John Wiley & Sons, Ltd.This publication has 17 references indexed in Scilit:
- Biology of tumor necrosis factor‐α– implications for psoriasisExperimental Dermatology, 2004
- Spontaneous Development of Psoriasis in a New Animal Model Shows an Essential Role for Resident T Cells and Tumor Necrosis Factor-αThe Journal of Experimental Medicine, 2004
- Dimethylfumarate Is a Potent Inducer of Apoptosis in Human T CellsJournal of Investigative Dermatology, 2003
- Changing paradigms in dermatology: tumor necrosis factor alpha (tnf-α) blockade in psoriasis and psoriatic arthritisClinics in Dermatology, 2003
- Inhibition of Dendritic Cell Differentiation by Fumaric Acid EstersJournal of Investigative Dermatology, 2001
- Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic useBritish Journal of Dermatology, 1999
- The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine networkBritish Journal of Dermatology, 1998
- Dimethylfumarate Is an Inhibitor of Cytokine-Induced E-Selectin, VCAM-1, and ICAM-1 Expression in Human Endothelial CellsBiochemical and Biophysical Research Communications, 1997
- Methotrexate for psoriasisClinical and Experimental Dermatology, 1996
- The mechanisms of action of cyclosporin A in the treatment of psoriasisImmunology Today, 1993